Clinical and translational radiation oncology · 2026
Radiotherapy quality assurance in the Danish breast cancer Group RT Natural trial.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Høgsbjerg Kristine Wiborg, Thomsen Mette Skovhus, Boye Kristian, Jensen Ingelise, Bekke Susanne Nørring, Lorenzen Ebbe Laugaard, Nissen Henrik Dahl, Saini Abhilasha, Dybvik Kjell Ivar, Wieslander Elinore, Tømmerås Veronika, Mikalsen Stine Gyland, Isacson Ulf, Grahn Camilla, Perander Kristine, Uhláriková Miroslava, Nygaard Britt, Holmeset Ida Marie, Far Manríquez Rodrigo El, Buhaug Kari Petrine, Jensen Maj-Britt Raaby, Overgaard Jens, Offersen Birgitte Vrou, DBCG RT Committee
Аннотация
PURPOSE/OBJECTIVE: Partial breast irradiation (PBI) is standard for selected relatively low-risk breast cancer patients, aiming to minimise late effects while maintaining local control. The Danish Breast Cancer Group (DBCG) RT Natural trial investigated whether PBI could be safely omitted in selected patients. Here, we report the radiotherapy quality assurance in the trial, evaluating target coverage and doses to organs of interest against protocol criteria.
MATERIAL/METHODS: Eligible patients were women ≥ 60 years with T ≤ 20 mm, unilateral, unifocal, node-negative, hormone receptor-positive, HER2-normal, non-lobular invasive breast cancer. Patients were randomised 1:1 to PBI (40 Gy in 15 fractions) versus no radiotherapy. Treatment plans for all patients treated with PBI were prospectively collected in a centralised DICOM-RT database and evaluated for protocol compliance.
RESULTS: Data from the 238 patients receiving PBI were analysed. Dose coverage was high, with median V95% of 100% for the tumour bed and CTVp_PBI and 98% for the PTVp_PBI. Only 1% had a CTVp_PBI V95% below the intended 95%, whereas 22% had a PTVp_PBI V95% <95%. No patients exceeded 110% of the prescribed dose. Dose conformity was good with median whole-breast V40Gy of 21%.Ipsilateral median mean lung dose was 1.52 Gy, and median mean heart dose 0.25 Gy left / 0.12 Gy right with no violation of dose guidance. Respiratory gating did not significantly affect lung or heart doses.
CONCLUSION: PBI in the DBCG RT Natural trial provided robust target coverage with minimal high-dose volumes, and maintained low cardiac and pulmonary doses, consistent with protocol planning objectives.
MATERIAL/METHODS: Eligible patients were women ≥ 60 years with T ≤ 20 mm, unilateral, unifocal, node-negative, hormone receptor-positive, HER2-normal, non-lobular invasive breast cancer. Patients were randomised 1:1 to PBI (40 Gy in 15 fractions) versus no radiotherapy. Treatment plans for all patients treated with PBI were prospectively collected in a centralised DICOM-RT database and evaluated for protocol compliance.
RESULTS: Data from the 238 patients receiving PBI were analysed. Dose coverage was high, with median V95% of 100% for the tumour bed and CTVp_PBI and 98% for the PTVp_PBI. Only 1% had a CTVp_PBI V95% below the intended 95%, whereas 22% had a PTVp_PBI V95% <95%. No patients exceeded 110% of the prescribed dose. Dose conformity was good with median whole-breast V40Gy of 21%.Ipsilateral median mean lung dose was 1.52 Gy, and median mean heart dose 0.25 Gy left / 0.12 Gy right with no violation of dose guidance. Respiratory gating did not significantly affect lung or heart doses.
CONCLUSION: PBI in the DBCG RT Natural trial provided robust target coverage with minimal high-dose volumes, and maintained low cardiac and pulmonary doses, consistent with protocol planning objectives.